This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Pycnogenol
Pycnogenol is the most-trialed OPC extract on the market — a trademarked, standardized French maritime pine (Pinus pinaster) bark extract with >100 RCTs and a 2024 comprehensive review covering 39 …
Aliases (4)
Overview
What is Pycnogenol?
Pycnogenol is the most-trialed OPC extract on the market — a trademarked, standardized French maritime pine (Pinus pinaster) bark extract with >100 RCTs and a 2024 comprehensive review covering 39 RDP trials (n=2,009). Real, replicated effects on endothelial NO production, mild BP reduction (~3 mmHg systolic), chronic venous insufficiency, erectile function (with L-arginine), and modest endurance / joint / skin signals. Verdict for a 20yo MMA athlete: OPTIONAL-ADD. The mechanism is real but the floor effect for an already-healthy young athlete is significant — and Pycnogenol prices at ~5× generic grape seed extract for substantially overlapping OPC pharmacology. Pick one OPC for the stack; if budget permits and venous/connective-tissue support matters (varicosity family history, prolonged-standing training, joint recovery), Pycnogenol earns the premium. Otherwise generic GSE delivers ~80% of the benefit. Skip if pre-surgical (2 wk before), on anticoagulants, pregnant, or already covering OPC mechanism through grape seed / cocoa flavanols.
Pharmacokinetics
Research Indications
65-75% procyanidins
flavan-3-ol oligomers (dimers through heptamers, mostly catechin/epicatechin-based)
Phenolic acids
caffeic, ferulic, gallic, p-coumaric, vanillic, protocatechuic (the "Pycnogenol-specific" fraction)
Catechins
(+)-catechin and (−)-epicatechin monomers
Bioflavonoids
taxifolin (dihydroquercetin) prominent; small quantities of quercetin and kaempferol glycosides
Peptide Interactions
substrate-pairing synergy. Pycnogenol upregulates eNOS; arginine provides the substrate the enzyme converts to NO. Documented for ED (Prelox formulation, Sta…
arginine precursor with better oral bioavailability; cleaner substitute for L-arginine. Same logic.
complementary mitochondrial-bioenergetics support. Common in CV stacks. Top community pairing (30 of 165 reports).
top community pairing (52 of 165 reports). Independent and complementary mechanisms on endothelial function and inflammation.
Pycnogenol recycles ascorbate radicals; pairing extends the antioxidant cycle.
overlapping mechanism, can be redundant; pair only if targeting very high antioxidant/NO load (athletic).
adjunct flavonoid for allergy / asthma indications. Mast-cell stabilization synergy.
mild additive anti-platelet effect. Not a hard contraindication at typical doses but warrants discussion with prescribing physician if combined long-term.
additive GI / bleeding risk. Occasional NSAID use is fine; chronic NSAID + Pycnogenol is not.
(high-dose fish oil >3 g/day, vitamin E >800 IU, ginkgo, garlic extract) — pre-surgical bleeding risk compounds. Manage as a category, not per-supplement.
additive BP effect. The Liu 2004 trial *used* this synergy to reduce nifedipine dose; in unmonitored setting it can cause symptomatic hypotension.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety 5
Side Effects
- 1GI upset — nausea, mild stomach pain, occasional diarrhea, especially on empty stomach or at >200 mg single doses. Mitigated by food + splitting dose. Tannin/taxifolin content drives this.
- 2Dizziness — most common in users with already-low BP. Reflects the BP-lowering pharmacology. If baseline BP is ~110/70, Pycnogenol can push to symptomatic hypotension on first 1-2 weeks.
- 3Headache (paradoxical — usually transient first week)
- 4Mouth ulcers / taste disturbance
- 5Fatigue or "spaced out" sensation (rare, reported in community data but not clearly drug-related)
When to Stop
- Allergic reactions — pine pollen allergic users may rarely cross-react. Clinical history of pine, cedar, or birch pollen severe allergy warrants caution.
- Hepatic effects — extremely rare. Two case reports of transient ALT elevation in long-term users; both resolved on discontinuation. Not a routine monitoring concern.
- Weeks 1-2 dose calibration — if dizziness on standing, drop to 50 mg/day or pause. If GI upset, take with larger meal, split BID, or pause.
- Pre-surgical 2-week rule — discontinue 14 days before any planned surgery (including dental). Anti-platelet effect is mild but real. Same rule applies before contact-sport competition where significant lacerations are anticipated.
- First-time combat-sport competition (MMA-specific): Conservatively discontinue 7-14 days before a fight if drug-tested or if visible bruising/lacerations are part of the cosmetic/medical-clearance picture. Not WADA-banned, so testing is irrelevant; the issue is purely mechanical (slightly elevated bleeding).
- Insufficient safety data. Pycnogenol is not contraindicated based on known mechanism, but no adequately powered safety trials exist in pregnant women. Conventional medical advice is to avoid in pregnancy and lactation. Defer to OB-GYN if pregnancy is planned or possible.
- The Trebatická 2006 ADHD trial (1 mg/kg/day) demonstrated tolerability in children for 1 month. No long-term pediatric safety data. Parental decision in consultation with pediatrician.
References
Weichmann F, Rohdewald P 2024 — Pycnogenol® clinical studies comprehensive review
39 RDP trials, n=2,009; canonical modern reference (sponsor-affiliated; treat effect sizes as upper bound).
View StudyNishioka K et al. 2007 — Pycnogenol augments endothelium-dependent vasodilation in humans
mechanistic confirmation that the vascular effect is NO-dependent (180 mg/day × 2 weeks, NOS-inhibitor abolishes effect).
View StudyLiu X et al. 2004 — Pycnogenol improves endothelial function of hypertensive patients
100 mg/day × 12 weeks reduced nifedipine dose in 58 mild hypertensives.
View StudyZhang Z et al. 2018 — Pycnogenol supplementation on blood pressure meta-analysis
9 RCTs, n=549, −3.22 SBP / −3.11 DBP mmHg at 150-200 mg/day.
View StudyTrebatická J et al. 2006 — Pycnogenol for ADHD in children
61 pediatric patients, 1 mg/kg × 1 month, significant hyperactivity reduction vs placebo.
View StudyStanislavov R, Nikolova V, Rohdewald P 2008 — Prelox (Pycnogenol + L-arginine) for ED
50 men, IIEF doubled, intercourse frequency >2× vs placebo.
View StudyCesarone MR et al. 2024 — Pycnogenol for symptomatic hand osteoarthritis
4-week registry; added to standard care improved pain and grip strength.
View StudyBelcaro G et al. 2024 — Pycnogenol vs elastic compression in CVI
18.3% vs 4.4% evening leg-volume reduction; superior microcirculatory measures.
View StudyBelcaro G et al. 2025 — Pycnogenol for CVI in diabetics
150 mg/day vs compression in 58 diabetic CVI patients; superior at 8 weeks.
View StudyVinciguerra G et al. 2013 — Pycnogenol for athletic performance and triathlon
200 mg/day × 8 weeks; 100-min triathlon improved 10.8 min vs 4.6 min in controls.
View StudyMalekahmadi M et al. 2019 — Pycnogenol BP meta-analysis (independent)
confirms BP signal in independent meta-analytic re-analysis.
View StudyFogacci F et al. 2020 — PRISMA-compliant Pycnogenol BP meta-analysis
additional independent meta-analytic confirmation.
View StudyNi Z et al. 2002 — Pycnogenol for melasma
75 mg/day × 30 days reduced pigmentation in 30 Asian women with melasma.
View StudyEnseleit F et al. 2012 — Pycnogenol on endothelial function in CAD
replicated FMD improvement in coronary artery disease patients.
View StudyStanislavov R, Nikolova V 2003 — original Pycnogenol/L-arginine ED trial
earlier ED trial preceding the 2008 Prelox crossover RCT.
View StudyL-arginine and Pycnogenol ED meta-analysis 2023
confirms combination superiority for IIEF in mild-moderate ED.
View StudyHorphag Pycnogenol product monograph
official ingredient specification and trial database.
View StudyLatest research
- rctPycnogenol® relieves chronic venous insufficiency (CVI) in diabetics: a supplement registry studyBelcaro 2025 — 150 mg/day Pycnogenol outperformed compression on microcirculatory and clinical scores in diabetic CVI over 8 weeks.
- rctSupplementary management of symptomatic hand osteoarthritis with Pycnogenol®Cesarone 2024 — 4-week registry; Pycnogenol added to standard care improved pain and grip strength vs standard care alone in hand OA.
- rctImprovements in edema and microcirculation in chronic venous insufficiency with Pycnogenol® or elastic compressionBelcaro 2024 — Pycnogenol reduced evening leg volume 18.3% vs 4.4% with compression alone; superior on skin flux and tcPO2/PCO2.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.